Taligen Therapeutics Advances Corporate Growth Plan with Appointment of Jeffrey T. Walsh as Chief Business Officer
12/1/2008 8:59:28 AM
More...
|
In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop
10/7/2008 10:52:07 AM
More...
|
Data from In Vivo Disease Models on Taligen Therapeutics' Pipeline Candidates to be Presented at the XXII International Complement Workshop
9/26/2008 11:19:39 AM
More...
|
Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO
7/23/2008 7:19:49 AM
More...
|
Taligen Therapeutics Secures $65 Million Series B Financing
2/1/2008 8:17:50 AM
More...
|
Taligen Therapeutics Announces Successful Achievement Of Series A Milestone
8/2/2006 12:31:12 PM
More...
|